論文・技術情報追加のお知らせ

1. Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases.

BVに関連する予期せぬ有害事象を検出

対象DB：FAERS,JADER

2. Drug-induced second tumors: a disproportionality analysis of the FAERS database.

新薬含む二次がんリスクをFAERSで検出

対象DB：FAERS

3. Improved Pharmacovigilance Signal Detection Using Bayesian Generalized Linear Mixed Models.

AEの構造を考慮した新モデルでワクチン安全性解析

対象DB：FAERS,VAERS

4. Drug-induced cardiac arrest: a pharmacovigilance study from 2004-2024 based on FAERS database.

40超の薬剤で心停止リスク上昇を確認

対象DB：FAERS

5. Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study.

高齢者TNF阻害薬は感染リスク増、特に結核注意

対象DB：FAERS

6. Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system.

IL-1阻害薬アナキンラとカナキヌマブは注射部位反応や感染が主な副作用

対象DB：FAERS

7. Safety Profile of Amantadine: A Comprehensive Analysis of Real-World Adverse Events from the FDA Adverse Event Reporting System Database.

アマンタジンは神経精神系副作用が多く、高齢女性に注意が必要

対象DB：FAERS

8. Drug-Associated Pemphigus Reported by Physicians: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.

医師報告の薬剤性天疱瘡をFAERSで解析

対象DB：FAERS

9. Multidimensional Assessment of Psychiatric Adverse Events Related to Proton Pump Inhibitors: A Real-World, Pharmacovigilance Study.

PPIは精神副作用と遺伝的関連あり

対象DB：FAERS

10. Proton pump inhibitors use and risk of type 2 diabetes mellitus: correlation analysis, prediction model construction, and key genes identification.

PPI使用はT2DMリスク上昇と関連、AGT・JAK2関与

対象DB：FAERS

11. A pharmacovigilance analysis of post-marketing safety of durvalumab.

デュルバルマブで新規有害事象報告、特に高齢男性

対象DB：FAERS

12. Nephrotoxicity of direct factor Xa inhibitors: a pharmacovigilance study using real-world data from the Federal Adverse Event Reporting System database.

FXa阻害薬で腎毒性リスク、特にエドキサバン

対象DB：FAERS

13. Antiplatelet-Proton Pump Inhibitor Interactions and Arterial Thrombotic Events: A Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis.

クロピドグレルとPPI併用で血栓リスク増

対象DB：FAERS

14. Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database.

インスリングラルギンに新たな副作用シグナル

対象DB：FAERS

15. Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.

ピルフェニドンとニンテダニブで副作用に差

対象DB：FAERS,JADER

16. Age-related adverse effects of Tamoxifen in female breast cancer patients: Insights from the FDA's adverse event reporting system.

タモキシフェンの副作用は加齢で増加

対象DB：FAERS

17. Cardiovascular safety of Janus kinase inhibitors: A pharmacovigilance study from 2012-2023.

JAK阻害薬に心血管リスク、慎重な監視を

対象DB：FAERS

18. Adverse Events Associated with Apremilast and Deucravacitinib for Psoriasis: A Pharmacovigilance Study Based on the FAERS Database.

皮膚・消化器AEsに性差、慎重な使用を

対象DB：FAERS

19. Thrombotic adverse events associated with TNF-alpha blockers: a real-world pharmacovigilance analysis of the FAERS database.

TNF阻害薬は血栓リスクと関連、特に産後に注意

対象DB：FAERS

20. Suicidal thoughts and behaviors associated with fluoroquinolone antibiotics: a real-world pharmacovigilance analysis.

フルオロキノロンは全体で自殺念慮のシグナルなし

対象DB：FAERS

21. The Cardiac and Renal Safety of Semaglutide in Patients with Type 2 Diabetes: A Real-World Study Based on FAERS.

セマグルチドは糖尿病患者で腎心臓安全性に問題なし

対象DB：FAERS

22. Women and adverse drug reactions: 56 years of analysis of real-world data collected in the FDA adverse event reporting system (FAERS) database.

FAERSデータで女性の副作用リスクを56年分析

対象DB：FAERS

23. Delirium risk associated with Esketamine, Sevoflurane, Propofol, and Dexmedetomidine: A Real-World Study Based on the FDA Adverse Event Reporting System.

プロポフォールら3薬でせん妄リスク増加

対象DB：FAERS

24. Post-Marketing Safety of Spinal Muscular Atrophy Therapies: Analysis of Spontaneous Adverse Drug Reactions from EudraVigilance.

SMA治療薬の安全性を市販後報告で評価

対象DB：EudraVigilance

25. Argatroban plus Dual Antiplatelet Therapy versus Dual Antiplatelet Alone for Acute Atherothrombotic Cerebral Infarction.

DAPT＋アルガトロバンの有効性は同等

対象DB：DPC

26. Trends and outcomes of chemotherapy timing in critically ill patients with hematologic malignancies using a Japanese national database.

ICU中の化学療法は一定の生存率を維持

対象DB：DPC

27. Treatment Persistence of Paliperidone Palmitate 3-Month in Patients With Schizophrenia: A Japan Medical Data Center Claims Database Analysis.

PP3Mの1年持続率は約77%と高率

対象DB：JMDC

28. Characteristics of people with severe mental illness excluded from incentivised physical health checks in the UK: electronic healthcare record study.

SMI患者の健康診断除外は約28%

対象DB：CPRD

29. Developing prediction models for electrolyte abnormalities in patients indicated for antihypertensive therapy: evidence-based treatment and monitoring recommendations.

電解質異常予測モデルは臨床応用可能

対象DB：CPRD

30. Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.

中止予測モデルは精度低く臨床有用性乏しい

対象DB：CPRD

31. Antimicrobial Resistance Trends, Predictors, and Burden in England: A retrospective study using the Clinical Practice Research Datalink from 2015-2021.

AMR感染は医療費・死亡率を大幅増加

対象DB：CPRD

32. Medications used for seizure-emergency management in the UK community: A clinical practice research datalink retrospective database study.

緊急発作薬使用者は7%、受診頻度高い

対象DB：CPRD

33. Incretin-Based Drugs and the Incidence of Endometrial Cancer Among People with Type 2 Diabetes: Active Comparator New-User Design.

GLP-1製剤とDPP-4阻害薬で子宮癌リスク増加

対象DB：CPRD